VENCF (Vencanna Ventures) ROE % Adjusted to Book Value: -918.20% (As of Jan. 2026)


What is Vencanna Ventures ROE % Adjusted to Book Value?

Vencanna Ventures VENCF +80.00% ROE % Adjusted to Book Value is -918.20% as of Jan. 2026. The stock has 4 warning signs investors should review.

Vencanna Ventures's ROE % for the quarter that ended in Jan. 2026 was -45.91%. Vencanna Ventures's PB Ratio for the quarter that ended in Jan. 2026 was 0.05. Vencanna Ventures's ROE % Adjusted to Book Value for the quarter that ended in Jan. 2026 was -918.20%.

Vencanna Ventures ROE % Adjusted to Book Value Related Terms

Vencanna Ventures ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Vencanna Ventures's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vencanna Ventures ROE % Adjusted to Book Value Chart

Vencanna Ventures Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -11.67 -5.90 -3.64 0.00 -27.02

Vencanna Ventures Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -56.93 -33.45 -21.22 -686.25 -918.20

VENCF vs ZTS: ROE % Adjusted to Book Value Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Vencanna Ventures's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vencanna Ventures ROE % Adjusted to Book Value vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vencanna Ventures's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Vencanna Ventures's ROE % Adjusted to Book Value falls into.


Vencanna Ventures ROE % Adjusted to Book Value Calculation

Vencanna Ventures's ROE % Adjusted to Book Value for the fiscal year that ended in Apr. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-68.89% / 2.55
=-27.02%

Vencanna Ventures's ROE % Adjusted to Book Value for the quarter that ended in Jan. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-45.91% / 0.05
=-918.20%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -918.20% mean?
Vencanna Ventures (VENCF) has a ROE % Adjusted to Book Value of -918.20% as of Jan. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Vencanna Ventures and its competitors.
Is Vencanna Ventures' ROE % Adjusted to Book Value too high?
Vencanna Ventures' current ROE % Adjusted to Book Value is -918.20%.
How does Vencanna Ventures' ROE % Adjusted to Book Value compare to ZTS?
Vencanna Ventures' ROE % Adjusted to Book Value of -918.20% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?
A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Vencanna Ventures and its competitors. Vencanna Ventures's current ROE % Adjusted to Book Value is -918.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vencanna Ventures stock overvalued right now?
Vencanna Ventures (VENCF) has a current ROE % Adjusted to Book Value of -918.20%. The current ROE % Adjusted to Book Value is -918.20%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Vencanna Ventures (VENCF), the current ROE % Adjusted to Book Value is -918.20% as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vencanna Ventures Business Description

Other Exchanges VENI:Canada
Address 622 5th Avenue SW, Suite 200, Calgary, AB, CAN, T2P 0M6
Vencanna Ventures Inc aims to provide investors with a diversified, high-growth, cannabis investment plan through strategic investments and acquisitions focused throughout the value chain (cultivation, processing, and distribution), including ancillary businesses. The company generates the majority of its revenue from the United States.